Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Alpha Cognition Inc ACOG

Alpha Cognition Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is engaged in developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Company’s pipeline includes ALPHA-1062, ALPHA-0602, and ALPHA-0702 and ALPHA-0802 (GEMs). The Company’s ALPHA-1062... see more

NDAQ:ACOG - Post Discussion

Alpha Cognition Inc > Pharma Exec's on marketing and comm. in post Covid-19 era
View:
Post by culturedpiggy01 on Dec 16, 2021 4:45pm

Pharma Exec's on marketing and comm. in post Covid-19 era

came across this great article summarizing a conversation between leading pharmaceutical executives including ACOG.v 's COO Lauren D’Angelo about delivering information and communication channels in the post COVID-19 era and its impact on sales and marketing. Read here: https://www.pharmexec.com/view/the-future-of-sales-and-marketing-how-to-deliver-information-in-the-era-of-covid-19
 
td, $ACOG.v trading at $1.21 with market cap at $74.41 M
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities